SynthesisJournal of robotic surgery2026
Probabilistic multi-criteria decision analysis comparing single-port and multiport robot-assisted radical prostatectomy and partial nephrectomy: A secondary analysis of systematic review data.
Synthesis in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probabilistic Multicriteria Decision Analysis of Minimally Invasive Treatments for Benign Prostatic Obstruction: A Secondary Analysis of Network Meta-Analysis Data.Lower urinary tract symptoms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare single-port (SP) and multiport (MP) robot-assisted radical prostatectomy (RARP) and partial nephrectomy (RAPN) using probabilistic multi-criteria decision analysis (MCDA) integrating perioperative, functional, and oncological outcomes. A secondary analysis used meta-analytic data from Ficarra et al. (2025) comparing SP and MP across 26 RARP and 9 RAPN studies. Eleven criteria were evaluated for RARP and nine for RAPN. Effect estimates and 95% confidence intervals informed normal distributions for Monte Carlo simulation (50,000 iterations). Outcomes were mapped to a 0–1 scale using clinically interpretable anchors (± 1.5 for standardized mean difference; ± log[3] for log odds ratio). Five prespecified weighting scenarios (equal, safety, oncology, recovery, balanced) produced preference probabilities and net advantages with 95% credible intervals (CrI). Anchor perturbation assessed robustness. For RARP, SP showed higher preference probabilities across all scenarios (P[SP-RARP > MP-RARP] = 92.9% to > 99.9%), with the largest net advantage under recovery weights (0.128; 95% CrI: 0.081–0.172), driven by length of stay, catheterization time, and estimated blood loss. For RAPN, SP was preferred under recovery weights (P[SP-RAPN > MP-RAPN] = 97.5%; net advantage: 0.046; 95% CrI: 0.000–0.092) but attenuated under safety (62.1%) and oncology (63.7%) weights, where warm ischemia time and major complications penalized SP. Findings were stable across anchor perturbations. A structural sensitivity analysis excluding warm ischemia time (WIT) from the RAPN safety- and recovery-focused scenarios increased the SP preference probability in both RAPN scenarios; however, the safety-focused scenario retained substantial uncertainty (95% CrI crossing zero). SP-RARP demonstrates consistent probabilistic advantage regardless of priority weighting. For RAPN, SP advantage is scenario-dependent, with recovery benefit but considerable uncertainty under safety and oncology priorities. This framework provides transparent decision support, although conclusions remain contingent on the quality of underlying observational evidence.
Indexed as
Identifiers
41931172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.